Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry

Harald Kaemmerer, Matthias Gorenflo, Dörte Huscher, David Pittrow, Christian Apitz, Helmut Baumgartner, Felix Berger, Leonhard Bruch, Eva Brunnemer, Werner Budts, Martin Claussen, Gerry Coghlan, Ingo Dähnert, Michele D'Alto, Marion Delcroix, Oliver Distler, Sven Dittrich, Daniel Dumitrescu, Ralf Ewert, Martin Faehling, Ingo Germund, Hossein Ardeschir Ghofrani, Christian Grohé, Karsten Grossekreymborg, Michael Halank, Georg Hansmann, Dominik Harzheim, Attila Nemes, Kalman Havasi, Matthias Held, Marius M Hoeper, Michael Hofbeck, Wolfgang Hohenfrost-Schmidt, Elena Jurevičienė, Lina Gumbienè, Hans-Joachim Kabitz, Hans Klose, Thomas Köhler, Stavros Konstantinides, Martin Köestenberger, Rainer Kozlik-Feldmann, Hans-Heiner Kramer, Cornelia Kropf-Sanchen, Astrid Lammers, Tobias Lange, Philipp Meyn, Oliver Miera, Katrin Milger-Kneidinger, Rhoia Neidenbach, Claus Neurohr, Christian Opitz, Christian Perings, Bjoern Andrew Remppis, Gabriele Riemekasten, Laura Scelsi, Werner Scholtz, Iveta Simkova, Dirk Skowasch, Andris Skride, Gerd Stähler, Brigitte Stiller, Iraklis Tsangaris, Carmine Dario Vizza, Anton Vonk Noordegraaf, Heinrike Wilkens, Hubert Wirtz, Gerhard-Paul Diller, Ekkehard Grünig, Stephan Rosenkranz, Harald Kaemmerer, Matthias Gorenflo, Dörte Huscher, David Pittrow, Christian Apitz, Helmut Baumgartner, Felix Berger, Leonhard Bruch, Eva Brunnemer, Werner Budts, Martin Claussen, Gerry Coghlan, Ingo Dähnert, Michele D'Alto, Marion Delcroix, Oliver Distler, Sven Dittrich, Daniel Dumitrescu, Ralf Ewert, Martin Faehling, Ingo Germund, Hossein Ardeschir Ghofrani, Christian Grohé, Karsten Grossekreymborg, Michael Halank, Georg Hansmann, Dominik Harzheim, Attila Nemes, Kalman Havasi, Matthias Held, Marius M Hoeper, Michael Hofbeck, Wolfgang Hohenfrost-Schmidt, Elena Jurevičienė, Lina Gumbienè, Hans-Joachim Kabitz, Hans Klose, Thomas Köhler, Stavros Konstantinides, Martin Köestenberger, Rainer Kozlik-Feldmann, Hans-Heiner Kramer, Cornelia Kropf-Sanchen, Astrid Lammers, Tobias Lange, Philipp Meyn, Oliver Miera, Katrin Milger-Kneidinger, Rhoia Neidenbach, Claus Neurohr, Christian Opitz, Christian Perings, Bjoern Andrew Remppis, Gabriele Riemekasten, Laura Scelsi, Werner Scholtz, Iveta Simkova, Dirk Skowasch, Andris Skride, Gerd Stähler, Brigitte Stiller, Iraklis Tsangaris, Carmine Dario Vizza, Anton Vonk Noordegraaf, Heinrike Wilkens, Hubert Wirtz, Gerhard-Paul Diller, Ekkehard Grünig, Stephan Rosenkranz

Abstract

Introduction: Pulmonary hypertension (PH) is a common complication in patients with congenital heart disease (CHD), aggravating the natural, post-operative, or post-interventional course of the underlying anomaly. The various CHDs differ substantially in characteristics, functionality, and clinical outcomes among each other and compared with other diseases with pulmonary hypertension.

Objective: To describe current management strategies and outcomes for adults with PH in relation to different types of CHD based on real-world data.

Methods and results: COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension) is a prospective, international PH registry comprising, at the time of data analysis, >8200 patients with various forms of PH. Here, we analyzed a subgroup of 680 patients with PH due to CHD, who were included between 2007 and 2018 in 49 specialized centers for PH and/or CHD located in 11 European countries. At enrollment, the patients´ median age was 44 years (67% female), and patients had either pre-tricuspid shunts, post-tricuspid shunts, complex CHD, congenital left heart or aortic disease, or miscellaneous other types of CHD. Upon inclusion, targeted therapies for pulmonary arterial hypertension (PAH) included endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, and soluble guanylate cyclase stimulators. Eighty patients with Eisenmenger syndrome were treatment-naïve. While at inclusion the primary PAH treatment for the cohort was monotherapy (70% of patients), with 30% of the patients on combination therapy, after a median observation time of 45.3 months, the number of patients on combination therapy had increased significantly, to 50%. The use of oral anticoagulants or antiplatelets was dependent on the underlying diagnosis or comorbidities. In the entire COMPERA-CHD cohort, after follow-up and receiving targeted PAH therapy (n = 511), 91 patients died over the course of a 5-year follow up. The 5-year Kaplan-Meier survival estimate for CHD associated PH was significantly better than that for idiopathic PAH (76% vs. 54%; p < 0.001). Within the CHD associated PH group, survival estimates differed particularly depending on the underlying diagnosis and treatment status.

Conclusions: In COMPERA-CHD, the overall survival of patients with CHD associated PH was dependent on the underlying diagnosis and treatment status, but was significantly better as than that for idiopathic PAH. Nevertheless, overall survival of patients with PAH due to CHD was still markedly reduced compared with survival of patients with other types of CHD, despite an increasing number of patients on PAH-targeted combination therapy.

Keywords: adults; congenital heart disease; observational; pulmonary arterial hypertension; pulmonary hypertension; survival; targeted therapy.

Conflict of interest statement

COMPERA is supported by an educational grant from Bayer, GSK, OMT and Actelion. The authors declare no conflicts of interest in relation to the study.

Figures

Figure 1
Figure 1
Age distribution of the population with CHD-associated pulmonary arterial hypertension (PAH). Data represent the percentage of patients from each subgroup in the respective age groups. CHD, congenital heart disease.
Figure 2
Figure 2
Drug classes for targeted PAH therapy in the patients with CHD-associated PAH at inclusion and at last observation (mean/median observation time of 50.5/45.3 months respectively; for 512 patients with at least one follow-up). “Other therapy” includes soluble guanylate cyclase (sGC) stimulator, tyrosine kinase inhibitor, calcium channel blockers, and other PAH-specific trial therapies. Abbreviations: PCA, prostanoids.
Figure 3
Figure 3
Targeted mono- or combination therapy in 512 CHD patients with PAH, with at least one follow-up using different drug classes at inclusion and at last observation (mean/median observation time of 50.5/45.3 months respectively). CHD, congenital heart disease; PAH, pulmonary arterial hypertension
Figure 4
Figure 4
Anticoagulation/platelet inhibition regime in patients with CHD-associated PAH at inclusion and at last observation. Abbreviations: CHD, congenital heart disease; NOAC, non-vitamin K antagonists; vit, vitamin; PAH, pulmonary arterial hypertension
Figure 5
Figure 5
Kaplan–Meier 5-year survival estimates. (A) Comparison of all patients who underwent targeted PAH treatment for either congenital heart disease-associated pulmonary hypertension (CHD treated, total) or incident idiopathic PAH. The 5-year Kaplan–Meier survival estimate was 76% for PAH due to CHD and 54% for idiopathic PAH (p < 0.001). (B) Comparison of subgroups of patients with CHD and PAH under targeted PAH medication: (1) CHD-treated, total (green); (2) Eisenmenger-patients-treated (EM treated; purple); (3) non-Eisenmenger-PAH-patients (Non-EM treated; blue). The overall 5-year survival estimate was 76%, compared with 78% for the Eisenmenger patients, and 77% for the non-Eisenmenger-PAH-patients (p = 0.384). (C) Comparison of subgroups of patients with Eisenmenger syndrome due to complex or simple CHD. The 5-year Kaplan–Meier survival estimate was 81% for Eisenmenger syndrome caused by simple CHD and 64% for Eisenmenger syndrome due to complex CHD (p = 0.063). Kaplan–Meier survival estimates (top) and number of cases still under observation (bottom) are shown in tabular form. Abbreviations: CHD, congenital heart disease; non-EM, non-Eisenmenger-PAH-patients; PAH, pulmonary arterial hypertension.

References

    1. Kaemmerer H., Apitz C., Brockmeier K., Eicken A., Gorenflo M., Hager A., De Haan F., Huntgeburth M., Kozlik-Feldmann R.G., Miera O., et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int. J. Cardiol. 2018;272:79–88. doi: 10.1016/j.ijcard.2018.08.078.
    1. Galié N., Humbert M., Vachiéry J.-L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Noordegraaf A.V., Beghetti M., et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2016;37:67–119. doi: 10.1093/eurheartj/ehv317.
    1. Simonneau G., Montani D., Celermajer D.S., Denton C.P., Gatzoulis M.A., Krowka M., Williams P.G., Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 2019;53:1801913. doi: 10.1183/13993003.01913-2018.
    1. Brida M., Gatzoulis M.A. Pulmonary arterial hypertension in adult congenital heart disease. Heart. 2018;104:1568–1574. doi: 10.1136/heartjnl-2017-312106.
    1. Simonneau G., Gatzoulis M.A., Adatia I., Celermajer D.S., Denton C., Ghofrani H.A., Sánchez M.A.G., Kumar R.K., Landzberg M., Machado R., et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013;62:D34–D41. doi: 10.1016/j.jacc.2013.10.029.
    1. Kaemmerer H., Apitz C., Brockmeier K., Eicken A., Gorenflo M., Hager A., De Haan F., Huntgeburth M., Kozlik-Feldmann R., Miera O. Pulmonary hypertension in grown-ups with congenital heart disease: Recommendations of the Cologne Consensus Conference 2016. Dtsch. Med. Wochenschr. (1946) 2016;141:S70–S79.
    1. Klinger J.R., Elliott C.G., Levine D.J., Bossone E., Duvall L., Fagan K., Frantsve-Hawley J., Kawut S.M., Ryan J.J., Rosenzweig E.B., et al. Therapy for pulmonary arterial hypertension in adults. Chest. 2019;155:565–586. doi: 10.1016/j.chest.2018.11.030.
    1. Franklin W.J., Parekh D.R., Safdar Z. Adult congenital heart disease and pulmonary arterial hypertension: The Texas adult congenital heart program experience. Postgrad. Med. 2011;123:32–45. doi: 10.3810/pgm.2011.11.2493.
    1. Duffels M., Engelfriet P., Berger R., Van Loon R., Hoendermis E., Vriend J.W., Van der Velde E.T., Bresser P., Mulder B. Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry. Int. J. Cardiol. 2007;120:198–204. doi: 10.1016/j.ijcard.2006.09.017.
    1. Verheugt C.L., Uiterwaal C.S.P.M., Van der Velde E.T., Meijboom F.J., Pieper P.G., Vliegen H.W., Van Dijk A., Bouma B.J., Grobbee D.E., Mulder B. Gender and outcome in adult congenital heart disease. Circulation. 2008;118:26–32. doi: 10.1161/CIRCULATIONAHA.107.758086.
    1. Safdar Z. Pulmonary hypertension: A woman’s disease. Tex. Heart Inst. J. 2013;40:302–303.
    1. Alonso-Gonzalez R., Lopez-Guarch C.J., Subirana-Domènech M.T., Ruiz J.M.O., González I.O., Cubero J.S., Del Cerro M.J., Salvador M.L., Dos Subira L., Gallego P., et al. Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. Int. J. Cardiol. 2015;184:717–723. doi: 10.1016/j.ijcard.2015.02.031.
    1. Favilli S., Spaziani G., Ballo P., Fibbi V., Santoro G., Chiappa E., Arcangeli C. Advanced therapies in patients with congenital heart disease-related pulmonary arterial hypertension: Results from a long-term, single center, real-world follow-up. Intern. Emerg. Med. 2015;10:445–450. doi: 10.1007/s11739-014-1185-1.
    1. Galié N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.-L., Barberà J.A., Beghetti M., Corris P., Gaine S.P., Gibbs J.S., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur. Heart J. 2009;30:2493–2537. doi: 10.1093/eurheartj/ehp297.
    1. Derk G., Houser L., Miner P., Williams R., Moriarty J., Finn P., Alejos J., Aboulhosn J. Efficacy of endothelin blockade in adults with f ontan physiology. Congenit. Heart Dis. 2015;10:E11–E16. doi: 10.1111/chd.12189.
    1. Kempny A., Hjortshøj C.S., Gu H., Li W., Opotowsky A.R., Landzberg M.J., Jensen A.S., Søndergaard L., Estensen M.-E., Thilén U., et al. Predictors of death in contemporary adult patients with eisenmenger syndrome. Circulation. 2017;135:1432–1440. doi: 10.1161/CIRCULATIONAHA.116.023033.
    1. Hoeper M.M., Huscher D., Ghofrani H.A., Delcroix M., Distler O., Schweiger C., Gruenig E., Staehler G., Rosenkranz S., Halank M., et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Int. J. Cardiol. 2013;168:871–880. doi: 10.1016/j.ijcard.2012.10.026.
    1. Olsson K.M., Delcroix M., Ghofrani H.A., Tiede H., Huscher D., Speich R., Grünig E., Staehler G., Rosenkranz S., Halank M., et al. Anticoagulation and survival in pulmonary arterial hypertension: Results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA) Circulation. 2014;129:57–65. doi: 10.1161/CIRCULATIONAHA.113.004526.
    1. Opitz C., Hoeper M.M., Gibbs J.S.R., Kaemmerer H., Pepke-Zaba J., Coghlan J.G., Scelsi L., D’Alto M., Olsson K., Ulrich S., et al. Pre-capillary, combined, and post-capillary pulmonary hypertension. J. Am. Coll. Cardiol. 2016;68:368–378. doi: 10.1016/j.jacc.2016.05.047.
    1. National Institutes of Health, US Library of Medicine COMPERA/COMPERA-KIDS. [(accessed on 11 May 2020)]; Available online:
    1. Stout K.K., Daniels C.J., Aboulhosn J.A., Bozkurt B., Broberg C.S., Colman J.M., Crumb S.R., Dearani J.A., Fuller S., Gurvitz M., et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: Executive summary: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 2019;73:1494–1563. doi: 10.1016/j.jacc.2018.08.1028.
    1. Coats A., Shewan L. Statement on authorship and publishing ethics in the international journal of cardiology. Int. J. Cardiol. 2011;153:239–240. doi: 10.1016/j.ijcard.2011.10.119.
    1. Tulloh R.M.R., Dimopoulos K., Condliffe R., Clift P., CHAMPION Steering Committee Management of adults with congenital heart disease and pulmonary arterial hypertension in the UK: Survey of current practice, unmet needs and expert commentary. Heart Lung Circ. 2017;27:1018–1027. doi: 10.1016/j.hlc.2017.10.018.
    1. Diller G.P., Körten M.-A., Bauer U.M., Miera O., Tutarel O., Kaemmerer H., Berger F., Baumgartner H. Current therapy and outcome of Eisenmenger syndrome: Data of the German National Register for congenital heart defects. Eur. Heart J. 2016;37:1449–1455. doi: 10.1093/eurheartj/ehv743.
    1. Vijarnsorn C., Durongpisitkul K., Chungsomprasong P., Bositthipichet D., Ketsara S., Titaram Y., Chanthong P., Kanjanauthai S., Soongswang J. Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts. PLoS ONE. 2018;13:e0195092. doi: 10.1371/journal.pone.0195092.
    1. Condliffe R.C., Clift P., Dimopoulos K., Tulloh R.M.R. Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. Pulm. Circ. 2018;8 doi: 10.1177/2045894018792501.
    1. Hascoët S., Fournier E., Jaïs X., Le Gloan L., Dauphin C., Houeijeh A., Godart F., Iriart X., Richard A., Radojevic J., et al. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Arch. Cardiovasc. Dis. 2017;110:303–316. doi: 10.1016/j.acvd.2017.01.006.
    1. Varela D., Teleb M., El-Mallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: A systematic review. Open Heart. 2018;5:e000744. doi: 10.1136/openhrt-2017-000744.
    1. Rosenkranz S. Pulmonary hypertension 2015: Current definitions, terminology, and novel treatment options. Clin. Res. Cardiol. 2015;104:197–207. doi: 10.1007/s00392-014-0765-4.
    1. Pulido T., Adzerikho I., Channick R.N., Delcroix M., Galié N., Ghofrani H.A., Jansa P., Jing Z.-C., Le Brun F.-O., Mehta S., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 2013;369:809–818. doi: 10.1056/NEJMoa1213917.
    1. Hoeper M.M., Apitz C., Grünig E., Halank M., Ewert R., Kaemmerer H., Kabitz H.-J., Kähler C., Klose H., Leuchte H., et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int. J. Cardiol. 2018;272:37–45. doi: 10.1016/j.ijcard.2018.08.082.
    1. Humbert M., Ghofrani H.A. The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax. 2016;71:73–83. doi: 10.1136/thoraxjnl-2015-207170.
    1. McGoon M.D., Benza R.L., Escribano-Subías P., Jiang X., Miller D.P., Peacock A.J., Pepke-Zaba J., Pulido T., Rich S., Rosenkranz S., et al. Pulmonary arterial hypertension: Epidemiology and registries. J. Am. Coll. Cardiol. 2013;62:D51–D59. doi: 10.1016/j.jacc.2013.10.023.
    1. Rose M.L., Strange G., King I., Arnup S., Vidmar S., O’Donnell C., Kermeen F., Grigg L., Weintraub R.G., Celermajer D.S. Congenital heart disease-associated pulmonary arterial hypertension: Preliminary results from a novel registry. Intern. Med. J. 2012;42:874–879. doi: 10.1111/j.1445-5994.2011.02708.x.
    1. Jansa P., Jarkovsky J., Al-Hiti H., Popelová J.R., Ambrož D., Zatočil T., Votavova R., Polacek P., Marešová J., Aschermann M., et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: A retrospective analysis of a nationwide registry. BMC Pulm. Med. 2014;14:45. doi: 10.1186/1471-2466-14-45.
    1. Van de Bruaene A., Delcroix M., Pasquet A., De Backer J., De Pauw M., Naeije R., Vachiery J.-L., Paelinck B., Morissens M., Budts W. The Belgian Eisenmenger syndrome registry: Implications for treatment strategies? Acta Cardiol. 2009;64:447–453. doi: 10.2143/AC.64.4.2041608.
    1. Idrees M., Al-Najashi K., Khan A., Al-Dammas S., Al-Awwad H., Batubara E., Al Otai A., AbdulHameed J., Fayed A., Kashour T. Pulmonary arterial hypertension in Saudi Arabia: Patients’ clinical and physiological characteristics and hemodynamic parameters. A single center experience. Ann. Thorac. Med. 2014;9:209–215. doi: 10.4103/1817-1737.140127.
    1. Benza R., Miller D.P., Barst R.J., Badesch D., Frost A.E., McGoon M.D. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142:448–456. doi: 10.1378/chest.11-1460.
    1. Pascall E., Tulloh R.M.R. Pulmonary hypertension in congenital heart disease. Future Cardiol. 2018;14:343–353. doi: 10.2217/fca-2017-0065.
    1. D’Alto M., Romeo E., Argiento P., Sarubbi B., Santoro G., Grimaldi N., Correra A., Scognamiglio G., Russo V., Calabrò R. Bosentan–sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int. J. Cardiol. 2012;155:378–382. doi: 10.1016/j.ijcard.2010.10.051.
    1. Iversen K., Jensen A.S., Jensen T.V., Vejlstrup N.G., Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial. Eur. Heart J. 2010;31:1124–1131. doi: 10.1093/eurheartj/ehq011.
    1. Manes A., Palazzini M., Leci E., Reggiani M.L.B., Branzi A., Galié N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: A comparison between clinical subgroups. Eur. Heart J. 2014;35:716–724. doi: 10.1093/eurheartj/eht072.
    1. Frogoudaki A.A., Gatzoulis M.A. Pulmonary arterial hypertension in congenital heart disease. Contin. Cardiol. Educ. 2018;4:23–33. doi: 10.1002/cce2.74.
    1. Baumgartner H., Bonhoeffer P., De Groot N.M., De Haan F., Deanfield J.E., Galié N., Gatzoulis M.A., Gohlke-Baerwolf C., Kaemmerer H., Kilner P., et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): The task force on the management of grown-up congenital heart disease of the european society of cardiology (ESC) Eur. Heart J. 2010;31:2915–2957. doi: 10.1093/eurheartj/ehq249.
    1. Lill M.C., Perloff J.K., Child J.S. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. Am. J. Cardiol. 2006;98:254–258. doi: 10.1016/j.amjcard.2006.01.083.
    1. Viswanathan S. Thromboembolism and anticoagulation after Fontan surgery. Ann. Pediatr. Cardiol. 2016;9:236–240. doi: 10.4103/0974-2069.189109.
    1. Deutsche Herzstiftung . Deutscher Herzbericht 2018. Deutsche Herzstiftung e.V.; Frankfurt am Main, Germany: 2018. Frankfurt am Main.
    1. Lowe B.S., Therrien J., Ionescu-Ittu R., Pilote L., Martucci G., Marelli A.J. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J. Am. Coll. Cardiol. 2011;58:538–546. doi: 10.1016/j.jacc.2011.03.033.
    1. Diller G.P., Kempny A., Inuzuka R., Radke R., Wort S.J., Baumgartner H., Gatzoulis M.A., Dimopoulos K. Survival prospects of treatment naïve patients with Eisenmenger: A systematic review of the literature and report of own experience. Heart. 2014;100:1366–1372. doi: 10.1136/heartjnl-2014-305690.
    1. Diller G.P., Dimopoulos K., Broberg C.S., Kaya M.G., Naghotra U.S., Uebing A., Harries C., Goktekin O., Gibbs S., Gatzoulis M.A. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: A combined retrospective and case-control study. Eur. Heart J. 2006;27:1737–1742. doi: 10.1093/eurheartj/ehl116.
    1. Nunan D., Aronson J., Bankhead C. Catalogue of bias: Attrition bias. BMJ Evid.-Based Med. 2018;23:21–22. doi: 10.1136/ebmed-2017-110883.
    1. Miller D.P., Gomberg-Maitland M., Humbert M. Survivor bias and risk assessment. Eur. Respir. J. 2012;40:530–532. doi: 10.1183/09031936.00094112.
    1. Delgado-Rodriguez M., Llorca J. Bias. J. Epidemiol. Community Health. 2004;58:635–641. doi: 10.1136/jech.2003.008466.
    1. Ling Y., Johnson M.K., Kiely D.G., Condliffe R., Elliot C.A., Gibbs S., Howard L.S., Pepke-Zaba J., Sheares K.K., Corris P.A., et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2012;186:790–796. doi: 10.1164/rccm.201203-0383OC.
    1. Farber H.W., Miller D.P., Poms A., Badesch D., Frost A.E., Rouzic E.M.-L., Romero A.J., Benton W.W., Elliott C.G., McGoon M.D., et al. Five-year outcomes of patients enrolled in the REVEAL registry. Chest. 2015;148:1043–1054. doi: 10.1378/chest.15-0300.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel